Which Pharmaceutical Companies are Seen as Leaders?

By Tyler Hassman, CEO

May 29, 2017

Corporate reputation plays an important role in enabling companies to further differentiate their products in highly competitive markets. As a result our team sought to better understand how pharmaceutical manufacturers are currently perceived. After surveying Canadian GPs, we noticed several trends. One of which was when assessing overall pharma leadership, there was no unanimous leader. However, when asked about specific therapeutic areas, GP perceptions of leadership varied for different companies.

Read More

We asked 180 Canadian physicians of which pharmaceutical company they have the highest opinion. Overall, there was no clear winner. However, when asked by disease areas, some leaders emerge.

Top companies seen as leader in…(% ranked 1-3)

  • Neurology: Novartis (46%); Roche (38%); Lilly (37%)
  • Cardiovascular Disease: Merck (51%); AstraZeneca (43%); Pfizer (43%)
  • Respiratory: GSK (69%); AstraZeneca (67%); Boehringer Ingelheim (56%)
  • Gastroenterology: Merk (67%); Pfizer (61%); Janssen (56%)
  • Diabetes: Lilly (50%); Novo Nordisk (40%); AstraZeneca (37%)
  • Psoriasis: Leo (65%); Galderma (57%); Janssen (24%)

Past Quick Polls

COVID-19 Impact on Women in Pharma

The COVID-19 crisis changed the way people work across industries including the pharma industry. MD Analytics teamed up with the professional association for women in the pharma industry Women Leaders in Pharma to conduct a study on the impact on of COVID-19 on women who work in the pharma industry.

read more

Pandemic’s Impact on HCPs Practices and Vaccination Campaign Perceptions

The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward? Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19.

read more

Remote Detailing for Pharma – Physicians’ perspectives

Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.

read more

We are here to answer your questions.

Share This